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Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate
(Mtx), suggesting an intrinsic resistance to this drug. Previous work has shown that cDNAs generated from osteosarcoma mRNA from a
fraction of patients contain sequence changes in the reduced folate carrier (RFC), the membrane protein transporter for Mtx. In this study,
the functionality of the altered RFC proteins was assessed by fusing the green fluorescent protein (GFP) to the C-terminal, and examining
the ability of the transfected constructs to complement a hamster cell line null for the carrier. Confocal microscopy and cell surface
biotinylation indicated that all altered proteins were properly localized at the cell membrane. Only one of those examined, Leu291Pro, was
unable to complement the null carrier line, but did bind Mtx at the cell surface. Thus, this alteration confers drug resistance since the carrier
is unable to translocate the substrate across the cell membrane. Three alterations, Ser46Asn, Ser4Pro and Gly259Trp, while able to
complement the carrier null line, conferred some degree of resistance to Mtx via a decreased rate of transport (Vmax). Another set of
alterations, Glu21Lys, Ala7Val, and the combined changes Thr222Ile, Met254Thr, complemented the carrier null line and did not confer
resistance to Mtx. Thus, some, but not all of these identified alterations in the RFC may contribute to the lack of responsiveness of
osteosarcomas to Mtx treatment.
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Osteosarcomas are common primary malignant bone
tumors occurring in children and adolescents, and are
generally treated with high doses of the antifolate metho-
trexate (Mtx). [1–5]. The conventional low-dose treatments
are ineffective, suggesting that such tumors may be intrin-
sically resistant to Mtx [6,7]. Previous studies [8–10] have
shown that approximately half of the osteosarcoma samples0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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Sciences University, Portland, OR, USA.examined at diagnosis have decreased expression of the
mRNA coding for the reduced folate carrier (RFC), the
membrane protein responsible for the transport of Mtx into
the cell [11]. As well, sequence changes in the coding
regions of rfc cDNAs generated from mRNAs in this
clinical material have also been identified in a small per-
centage of patients [12]. Interestingly, the resulting amino
acid changes in the RFC protein primarily occur in regions
predicted to face the cytosol or the extracellular environ-
ment, but not in transmembrane (TM) segments. It is unclear
whether these changes alter the function of the RFC protein
and contribute to the observed clinical resistance to Mtx.
In this report, the function of these altered RFC proteins
was examined by expressing each as a fusion protein with
enhanced green fluorescent protein (EGFP) in a hamster cell
line lacking RFC. One change confers a high level of
resistance to the drug while some others, a low level
suggesting that these alterations may be contributing factors
to in vivo resistance.
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2.1. Patient material
The source of the osteosarcoma tumor material in which
the sequence changes in rfc were identified was previously
described [12].
2.2. Reagents
Restriction endonucleases, ECL chemiluminescent
reagent, and streptavidin-biotinylated horseradish peroxi-
dase (HRP) were from Amersham Pharmacia Biotech.
Rabbit polyclonal and monoclonal anti-GFP antibodies,
and brefeldin A BODIPY 558/568 conjugate were from
Molecular Probes. Goat anti-rabbit IgG conjugated to HRP
was from Jackson Laboratories. Sulfosuccinimidyl-2-(bio-
tinamido) ethyl-1,3-dithiopropionate (EZ-Link sulfo-NHS-
SS-biotin) (biotin succinimide) was from Pierce Chemical
Co. Polybrene was from Sigma-Aldrich Chemical Company
and Geneticin (G418) from Gibco. [3V,5V,7V-3H] Mtx (23 Ci/
mmol) was purchased from Moravek Biochemicals Inc. and
purified by thin-layer chromatography before use as de-
scribed previously [13].
2.3. Constructs
The construction and characterization of human RFC
tagged at the C-terminus with the EGFP has been previously
described [14]. This modification has minimal effects on the
function and cellular localization of the protein [14,15]. An
EcoR1–Xho1 fragment containing the 3’ end of the rfc
cDNA fused to EGFP was subcloned into the pCDNA3
expression vector to allow the insertion of the altered
osteosarcoma rfc cDNAs.
Full-length human RFC cDNAs were obtained by re-
verse transcription-polymerase chain reaction (RT-PCR)
using RFC-specific primers on RNA isolated from osteo-
sarcoma samples. The full-length cDNAs with the indicated
sequence changes [12] were cloned into the BamH1 site of
pCDNA3. The BamH1–EcoR1 fragments from each of
these cDNAs were then subcloned into the BamH1–EcoR1
site of the 3V rfc-EGFP pCDNA3 vector (see above),
sequenced to confirm the presence of only the indicated
alterations and used for transfection studies.
2.4. DNA transfections
Transfection of the altered rfc plasmid clones into the
recipient MtxRII 5-3 cells was performed using 10 Ag of
purified DNA in polybrene/1.5 105 cells as previously
described [16]. This cell line is resistant to Mtx because it
does not transport the drug and has no detectable rfc
message. After transfection with DNA, the cells were
selected for growth in low levels of folinic acid (2 nM) or
in 1.2 mg/ml G418 for the line expressing Leu291Pro(alteration J). Single colonies were isolated and cloned by
limiting dilution from individual transfection experiments.
Two independent clones for each alteration were analyzed.
2.5. Phenotype testing
The transfectants were tested for Mtx resistance and
folinic acid growth requirement as previously described
[17]. Briefly, concentration response curves were generated
with various concentrations of the compounds with varying
numbers of cells and colony formation scored at 8 days of
growth. In both cases, the media lacked nucleosides. For
Mtx resistance, the D10 value is the drug concentration that
reduced survival to 10% while the D50 for folinic acid
growth is the nutrient concentration permitting 50% growth
as compared to wild-type. For each of these values, two
analyses were carried out for each cell line with less than
15% difference between each sample.
2.6. Kinetic analysis
The kinetic analyses for the determination of Vmax and Kt
for were carried out as previously described [13,17,18] with
at least two determinations for each cell line.
2.7. Western analysis
Total cellular extracts were prepared from various numb-
ers of cells by lysis on ice in lysis buffer (5 concentrated
protease-inhibitor-cocktail tablets [Roche], 1% NP-40, 0.5%
deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris–
HCl pH 7.4, 150 mM NaCl, 0.5 mM phenylmethylsulfonyl
fluoride [PMSF], and 2 AM orthovanadate). After centrifu-
gation at 12,000 g for 2 min at 4 jC, the soluble lysates
were subjected to SDS-PAGE and electroblotted onto nitro-
cellulose membranes. Detection of the fusion proteins was
as previously described [18]. Images were scanned, and
bands quantitiated using the BioRad Multi-Analyst pro-
gram. Only images in the linear range of the film were used
for quantitation.
2.8. Biotin labeling and detection
For cell surface biotinylation, equal numbers of cells
(f7 105) were washed twice with PBSCM (phosphate-
buffered saline buffer containing 0.1 mM CaCl2 and 1 mM
MgCl2), overlayed with 1 ml of PBSCM and biotinylated
with 1.5 mg/ml sulfo-NHS-SS biotin for 1 h at room
temperature. Cells were washed twice in 100 mM glycine/
PBSCM and once in ice-cold PBS. The cells were lysed as
described above and equal amounts of total cellular protein
were treated with mouse monoclonal anti-GFP antibody.
The lysates were rotated at 4j for 1 h. Protein G-Sepharose
was added and the incubation continued for 2 h. The resin–
lysate mixture was centrifuged for 2 min at 12,000 g, and
washed three times with a 10-fold excess of wash buffer
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mM Tris–HCl, pH 7.4, 50 mM NaCl). Samples were eluted
from the resin by incubation for 20 min at 56 jC with SDS-
PAGE buffer. The solubilized immunoprecipitates were
separated by SDS-PAGE (8% acrylamide) and electroblot-
ted onto nitrocellulose membranes.
The blots were blocked in 5% bovine serum albumin in
TBST (20 mM Tris–HCl, pH 7.6, 0.137 M NaCl, 0.2%
Tween 20) and biotinylated proteins detected with 1:2000
dilution of streptavidin-biotinylated HRP in TBST buffer
containing 0.5% BSA. After 1.5 h incubation, blots were
washed with TBST and visualized using ECL reagent and
Amersham Hyperfilm ECL film. Blots were stripped and
reprobed with polyclonal rabbit anti-GFP antibody followed
by goat anti-rabbit IgG conjugated to HRP. Images were
scanned and transfected protein levels were quantitated
using EGFP signal intensities and expressed relative to
wild-type (Table 2, column 2). The amount of surface
protein was normalized to an equivalent amount of wild-
type EGFP fusion protein (Table 2, column 3, ratio of
biotinylated protein to biotinylated wild-type). The relative
amount of surface protein expression was then corrected for
cellular expression levels by multiplying the relative fusion
protein levels by the relative surface labeled protein (Table
2, column 4).Fig. 1. Topology of RFC. The topology is on the basis of hydropathy plots, epito
mutagenesis [18]. Closed circled residues indicate those conserved among ham
alterations.2.9. Confocal microscopy
For confocal microscope analysis, cells were grown on
glass cover slips, treated with brefeldin A-BODIPY, and
fixed with 4% paraformaldehyde. Fluorescence was
detected using a LSM410 inverted Zeiss laser scanning
microscope with LSM410 software using a krypton/argon
laser as previously described [15]. Due to variations in the
intensities of the signals, different integration values were
used for each cell line to give the clearest representation of
the fusion protein distribution.
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Previous studies have indicated that approximately 14%
of samples from patients with osteosarcoma contained
nucleotide sequence changes in RFC [12]. The RFC pro-
teins expressed from these mRNAs could potentially have
altered function that might provide an explanation for the
intrinsic resistance of these tumors to Mtx treatment. To
evaluate the consequences of these changes (Fig. 1), RFC-
deficient hamster cells were transfected with constructs
containing these human altered RFCs fused to EGFP. This
is a useful system for assessing RFC characteristics sincepe insertion analysis [12,28], N-glycosylation [28], and cysteine scanning
ster, human, rat and mouse species. Arrows indicate the location of the
Fig. 2. Relative levels of EGFP fusion protein at the cell surface. Equal
numbers of cells expressing the various EGFP-fusion proteins were labeled
with biotin succinimide. EGFP-fusion proteins were immunoprecipitated
from equal amounts of total cellular protein, separated by SDS-PAGE and
examined by Western analysis as described in ‘‘Materials and methods’’.
Upper panel: the blot was probed using streptavidin-biotinylated HRP
complex. Lower panel: the blot was stripped and probed for EGFP fusion
proteins as described in ‘‘Materials and methods’’. The numbers on the left
indicate the size of protein markers in kilodaltons. The fusion protein
migrates as a broad band between 90 and 105 kDa since RFC is N-
glycosylated at N58 [29]. WT, wild-type; C (Ser46Asn); D (Glu21Lys); E
(Ala7Val); F (Ser4Pro); H (Gly259Trp); I (Thr222Ile, Met254Thr), J
(Leu291Pro).
Table 1
Functional characteristics of cell lines expressing EGFP altered fusion proteins
Cell linea Location Colonies/
Ag/106 cellsb
Folinic acid
D50 (nM)
Mtx
D10 (nM)
Mtx Kt (AM)c Mtx Vmax
(pmol/min/mg)c
Normalized Vmax
(pmol/min/mg)d
Vmax/Kt
Mtx RII 5-3 – – 200 250 – – – –
Wild-type – 2077 2 10 0.95F 0.3 2.0F 0.2 2.0 2.1
C (S46N) Between
TM1–TM2
1823 1.5 30 0.95F 0.2 0.4F 0.08 0.05 0.05
D (E21K) N-terminal 1018 2 8 0.7F 0.2 1.2F 0.16 1.8 2.5
E (A7V) N-terminal 1447 2 3 0.58F 0.2 2.0F 0.3 0.5 0.9
F (S4P) N-terminal 1608 1.8 40 0.6F 0.1 0.18F 0.05 0.25 0.4
H (G259W) Between
TM6–TM7
1960 1.5 30 0.92F 0.12 3.25F 1 0.9 1.0
I (T222I; M254T) Between
TM6–TM7
1420 1.5 12 0.7F 0.1 1.7F 0.6 1.4 2.0
J (L291P) Between
TM7–TM8
< 7 100e 180e – – – –
a Mtx RII 5-3 does not contain any RFC-EGFP constructs.
b Frequency of colony formation of constructs transfected into Mtx RII 5-3 recipient cell line.
c Values are averages of at least two independent analysesF standard error of the mean.
d Vmax was normalized for surface protein and corrected for cellular expression levels (Fig. 2, Table 2).
e Clones selected in G418.
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concentrations of folinic acid [14]. As shown in Table 1, all
but one of these fusion proteins was able to form colonies in
2 nM folinic acid. Colony formation varied between 50%
and 95% of wild-type, indicative of a functional RFC
protein. Cells expressing alteration J (Leu291Pro) were
unable to grow under these selective conditions, and cell
lines expressing this fusion protein were obtained using
G418 drug selection.
To further characterize these altered RFCs, the growth
requirements for folinic acid and sensitivity to Mtx were
assessed for cells expressing the proteins. As shown in Table
1, nearly all the cell lines had growth requirements for
folinic acid that were similar to the wild-type. In contrast,
cells expressing the J alteration (Leu291Pro) required a
similar level to that for the RFC-minus line (Mtx RII 5-3)
to sustain growth. The cellular sensitivity to Mtx enabled a
separation of the alterations into three general classes: (1)
little change in the Mtx sensitivity of the RFC-minus cell
line (alteration J); (2) similar or 3-fold lower sensitivities
compared to wild-type (alterations D, E, and I); and (3)
sequence changes that led to 3- to 4-fold increased resis-
tance compared to wild-type (alterations C, F, and H).
The transport properties for Mtx were further examined
by kinetic analysis. Cell lines expressing either alterations C
or H had similar affinities for Mtx as the wild-type express-
ing line, while those expressing changes D, E, F, and I had
slightly lower Kt values (Table 1). Sequence alterations E
and F were the most divergent, with f1.6-fold higher
affinity for Mtx. Before comparing the Vmax values, varia-
tions in protein expression levels or the proportion of RFC
at the cell surface were accommodated for using a previ-
ously described method [18]. Cells stably expressing each
altered protein were labeled with a membrane-impermeant
amide-reactive biotinylation reagent, and the fusion proteinswere immunoprecipitated from equal amounts of total
cellular protein using an excess of monoclonal antibody.
Subsequent Western analysis allowed a relative quantifica-
tion of the amounts of both biotinylated (cell surface) and
fusion protein (Fig. 2, Table 2). After correcting for differ-
ences in total fusion protein levels, there was a 0.6- to 8.5-
fold range in the relative surface protein expressed in the
mutant lines as compared to the wild-type expressing line.
When these expression variations were taken into account to
normalize the Vmax values for transport, the alterations could
be placed into one of two groups. One group, containing
alterations D and I, were able to transport Mtx with a similar
rate as wild-type. The second group containing changes C,
E, F and H expressing cell lines were less effective in
transporting the drug. Alteration C was least efficient with a
Table 2
Quantitation of EGFP fusion proteins at the cell surface
Cell line EGFP fusion
protein levela
Surface protein
normalized to
protein wild-typeb
Relative surface
corrected for
expression levelc
Wild-type 1.0 1.0 1.0
C (S46N) 3.2 2.7 8.5
D (E21K) 0.6 1.0 0.6
E (A7V) 1.2 3.3 4.1
F (S4P) 0.4 1.8 0.7
H (G259W) 1.1 3.3 3.6
I (T22I; M254T) 1.0 1.3 1.3
J (L291P) 0.7 3.2 2.2
a Numbers were generated from image in which the EGFP signal was
within the linear range of the film. Transfected protein levels were
quantitated using EGFP signal intensities and expressed relative to wild-
type.
b Values indicate the normalized amount of surface protein when
cellular EGFP fusion expression levels are equivalent to wild type (ratio of
biotinylated protein to biotinylated wild type/column 1).
c Values indicate the relative amount of surface protein expression
corrected for cellular expression levels (column 1 column 2).
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H changes had rates that were 4-, 8- and 2-fold less,
respectively. This is also reflected in the overall efficiency
of transport (Vmax/Kt, Table 1) where the C alteration is 40-
fold less efficient than wild-type, whereas the others vary
between 0.2 and 1.25 of wild-type.
Cells expressing alteration J were unable to transport the
drug; however, the biotinylation studies indicated that RFC-
fusion protein was being expressed on the cell surface (Fig.
2, Table 2). Binding studies indicated that such cells boundFig. 3. Confocal microscopy of transfected cell lines. The left image in each pa
endoplasmic and Golgi complex with brefeldin A BODIPY as described in ‘‘Ma
images. WT, wild-type; C (Ser46Asn); D (Glu21Lys); E (Ala7Val); F (Ser4Pro);Mtx with a Kd of 0.9 AM, similar to that of the wild-type
cells (0.8 AM), and with a normalized Bmax of 0.6 pmol/mg,
which was also similar to the wild-type value of 0.5 pmol/
mg. Thus, it appears that the defect conferred by this
alteration leads to an inability of the RFC protein to
translocate the drug across the cell membrane.
The biotinylation and transport studies indicate that in all
cases, the fusion protein was present at the cell surface.
Confocal microscopy was utilized to evaluate the distribu-
tion of the various fusion proteins throughout the entire cell
(Fig. 3). For all of the sequence changes, a vast majority of
the fusion protein was localized to the cell membrane with a
minor amount co-localizing with an endoplasmic reticu-
lum–Golgi-specific stain (brefeldin A BODIPY). In gener-
al, the fusion protein was discretely localized to the plasma
membrane similar to wild-type, but the fluorescence
appeared somewhat more diffuse in cells expressing alter-
ation D and especially alteration J. There also appeared to be
a slightly higher level of intracellular material for C and F
expressing cell lines. It should be noted that the EGFP
signal intensities do not reflect the relative expression levels
among the cell lines (see Materials and methods).4. Discussion
Osteosarcoma tumors typically have a poor response to
conventional dose protocols with Mtx. Various sequence
changes within the RFC gene have been identified in
osteosarcoma samples, raising the possibility that alterationsnel is EGFP fluorescence, and the center image is specific staining of the
terials and methods’’. The right panel is an overlay of the two preceding
H (Gly259Trp); I (Thr222Ile, Met254Thr), J (Leu291Pro).
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Mtx treatments. It is of interest to note that sequence
changes in RFC in childhood acute lymphoblastic leukemia
do not play a major role in resistance to Mtx [19]. In this
report, we have examined the consequences of several
clinically identified sequence changes on protein function,
by expressing the altered human RFCs as EGFP fusion
proteins in an RFC-deficient hamster cell line. The clinically
identified sequence changes in the RFC gene chosen for
analysis have previously been reported by Yang et al. [12]
and were identified from a panel of osteosarcoma patients.
Expression of the altered human RFC-EGFP fusion
proteins in the RFC-deficient hamster cell line indicated
that none of the alterations affected the ability of the protein
to localize to the cell membrane. The pattern of fluorescence
of the mutant fusion proteins as observed with confocal
microscopy is similar to that of the wild-type fusion protein,
and implies that the altered proteins are trafficking properly
and efficiently. Furthermore, most of the altered proteins
appeared functional, as assessed by the ability of the trans-
fected protein to rescue the RFC-deficient cell line under
low folate conditions. Phenotypic studies have indicated that
some of the alterations can confer resistance to Mtx, albeit at
low levels, while others have wild-type or increased sensi-
tivities to the drug.
The alteration Leu291Pro (J) was the only one unable to
complement the RFC deficiency of the recipient cell line.
Furthermore, cells expressing this RFC alteration retained
resistance to Mtx and increased growth requirements for
folinic acid. This is not a result of an inability of the protein
to traffic to the cell surface, as demonstrated by both
confocal microscopy and binding assays. As this alteration
is predicted to be located in the extracellular loop between
TM7 and 8, it could play a role in substrate binding.
However, the drug affinity of this mutant is the same as
for wild-type protein indicating little involvement in a
binding domain. Thus, it appears likely that the change to
proline at this site alters the conformation of the RFC
protein such that it interferes with translocation of the
substrate across the cell membrane.
Alteration of serine at position 46 to asparagine (C)
results in a 3-fold resistance to Mtx as compared to wild-
type. This phenotype is likely due to a dramatic decease in
the efficiency to translocate the substrate, as the Vmax of Mtx
transport is about 40-fold lower than for the wild-type
fusion protein. Interestingly, the same amino acid substitu-
tion (Ser46Asn) in mouse RFC has been identified in the
L1210 cell line, and leads to a 10-fold increase in resistance
to Mtx and a f40-fold reduction in Vmax compared to the
wild-type line [20]. These similar findings for RFC proteins
from different species indicate that this residue plays a key
role in the transport of the substrate. Furthermore, this site is
in a region predicted to be part of the substrate binding
domain [21,22]; numerous mutations in the loop between
TM1 and TM2 of RFC from several systems have been
shown to affect the binding affinity for substrates [23–25].While residue 46 does not appear to be directly involved in
the binding site, as the affinity for transport is unaffected by
the change (Table 1), it is nonetheless critical for efficient
substrate translocation. Although this alteration affects the
efficiency of transport, the folinic acid growth requirement
and the sensitivity to Mtx are not that different from those
alterations with 40-fold higher efficiency. This may reflect
the nature of the 8–10 day assays employed to measure
growth which allows sufficient accumulation of the either
the nutrient or drug to permit or limit growth, respectively.
Two other alterations (F and H) had an increased resis-
tance (3–4-fold) to Mtx as compared to the wild-type
expressing cells. Although alteration F (Ser4Pro) demon-
strates a slightly increased affinity for the drug, this effect is
likely offset by the significantly decreased Vmax of transport,
which is 8-fold lower than wild-type. Furthermore, this
change may affect the efficiency of trafficking to the cell
surface, as indicated by the surface protein biotinylation
data and confocal images. In contrast, it is unclear how the
change of glycine at 259 to tryptophan (H) leads to an
increased resistance to Mtx. The distribution of fusion
protein throughout the cell closely resembles the wild-type
protein, and while the Vmax of transport is 2-fold less than
wild-type, the affinity for Mtx is unaffected.
Three alterations, D (Glu21Lys), E (Ala7Val), and I
(Thr222Ile; Met254Thr) do not appear to have a role in
conferring an intrinsic Mtx resistance to osteosarcomas.
While change E demonstrates a 2-fold decrease in substrate
translocation efficiency as compared to wild-type, there is
also an increase in affinity, resulting in a 3-fold increase in
sensitivity to Mtx. The phenotypic parameters for alterations
D and I closely resemble those of the wild-type expressing
cells, with a slight decrease in Vmax offset by a slightly
higher affinity for the substrate. The increased affinity for
these altered proteins are likely secondary consequences of
conformational changes rather than an involvement in the
initial substrate binding, as they are located in regions that
face the cytosol.
Thus, in most cases, these changes confer a low level of
resistance to Mtx but not at the levels that are observed in
vivo where doses of the drug often reach the millimolar
range. Thus, the intrinsic resistance in vivo may be a
combination of several mechanisms and these sequence
level changes could be contributing factors. The potential
of several mechanisms of resistance including both quanti-
tative and qualitative changes in RFC may contribute to the
rationale for individualized chemotherapeutic strategies
[26].
It remains possible, however, that the full effect of these
alterations on RFC function has not been observed, as this
functional analysis was carried out in a heterologous system
where the human RFC was expressed in a hamster back-
ground. Although a wild-type human RFC can complement
the RFC deficiency in the hamster cell [27], previous work
has indicated that other factors may be required for the full
spectrum of transport activities associated with the human
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may influence the properties of RFC; mouse RFC expressed
in rat intestinal IEC-cells yields two kinetically different
transport activities differing in pH optima, whereas expres-
sion in murine leukemia cells yields a single transport
activity [29]. Thus, it may be informative to express these
fusion proteins in an osteosarcoma cell line to ascertain
whether there is an increased resistance to Mtx.
It is important to point out that the sequence changes
identified in the initial material were heterozygous, being
present with the wild-type allele [12]. Previous work has
indicated that alterations conferring resistance to Mtx as a
result of defective folate transport are genetically recessive
[30] and thus for the resistant phenotype to be detected, the
wild-type allele must be inactivated. Lack of RNA from
these tumor samples precluded an investigation of the wild-
type and sequence-altered RFC in these tumor samples.
Silencing of RFC expression by promoter methylation has
been reported in cell lines [31]. It is possible that the wild-
type allele is not expressed in these tumor cells and, if this is
the case, then some of these altered forms of RFC could
contribute to low levels of intrinsic resistance to Mtx. Thus,
studies similar to those described here on additional samples
with altered RFCs in conjunction with analyses of RNA
expression will need to be performed to assess the role
sequence changes and allele inactivation have in relation to
intrinsic drug resistance in osteosarcomas.Acknowledgements
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